Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Accumulated Expenses: 2014-2024

Historic Other Accumulated Expenses for ImmunityBio (IBRX) over the last 11 years, with Dec 2024 value amounting to $1.1 million.

  • ImmunityBio's Other Accumulated Expenses rose 49.93% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 49.93%. This contributed to the annual value of $1.1 million for FY2024, which is 46.65% up from last year.
  • ImmunityBio's Other Accumulated Expenses amounted to $1.1 million in FY2024, which was up 46.65% from $716,000 recorded in FY2023.
  • ImmunityBio's 5-year Other Accumulated Expenses high stood at $8.8 million for FY2020, and its period low was $716,000 during FY2023.
  • Over the past 3 years, ImmunityBio's median Other Accumulated Expenses value was $1.1 million (recorded in 2024), while the average stood at $1.1 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 1,037.55% in 2020, then crashed by 70.56% in 2021.
  • Over the past 5 years, ImmunityBio's Other Accumulated Expenses (Yearly) stood at $8.8 million in 2020, then crashed by 70.56% to $2.6 million in 2021, then plummeted by 37.26% to $1.6 million in 2022, then slumped by 56.02% to $716,000 in 2023, then skyrocketed by 46.65% to $1.1 million in 2024.